Who makes PAT-001, 0.1%?

PAT-001, 0.1% is developed by Patagonia Pharmaceuticals, LLC.

Last reviewed 2026-04-19 · How we verify

PAT-001, 0.1%

Patagonia Pharmaceuticals, LLC · Phase 2 active Small molecule

At a glance

Generic name	PAT-001, 0.1%
Also known as	PAT-001
Sponsor	Patagonia Pharmaceuticals, LLC
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Safety and Tolerability Study of Topical PAT-001 in Congenital Ichthyosis (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

PAT-001, 0.1% CI brief — competitive landscape report
PAT-001, 0.1% updates RSS · CI watch RSS
Patagonia Pharmaceuticals, LLC portfolio CI